Drug Discovery

Pharmacology

Volumn , Issue , 2009, Pages 475-560

  Erhardt, Paul ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957700315     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369521-5.00019-1     Document Type: Chapter

References (84)

1. Green Chemistry Syntheses and Process (Part 1); Green Engineering (Part 2) 2000, Oxford Univ Press, Cary, NC. P.T. Anastas, L.G. Heine, T.C. Williamson (Eds.).
2. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry 2004, Lippincott Williams & Wilkins, Baltimore, MD. 11th ed. J.H. Block, J.M. Beale (Eds.).
3. Design of Prodrugs 1985, Elsevier, Amsterdam, The Netherlands. H. Bundgaard (Ed.).
4. Drug Discovery and Development, Volume 1 Drug Discovery 2006, John Wiley & Sons, Hoboken, NJ. M.S. Chorghade (Ed.).
5. Fundamental Toxicology 2006, RSC Pub, Cambridge, United Kingdom. J.H. Duffus, H.G. Worth (Eds.).
6. Computer Applications in Pharmaceutical Research and Development 2006, John Wiley & Sons, Hoboken, NJ. S. Ekins (Ed.).
7. Drug Metabolism - Databases and High-Throughput Testing During Drug Design and Development 1999, IUPAC/Blackwell, Geneva, Switzerland. P.W. Erhardt (Ed.).
8. Analog-based Drug Discovery 2006, IUPAC/Wiley-VCH Verlag GmbH, Wenheim, Germany. J. Fischer, C.R. Ganellin (Eds.).
9. Substituent Constants for Correlation Analysis in Chemistry and Biology 1979, John Wiley & Sons, New York, NY. C. Hansch, A. Leo (Eds.).
10. Fundamentals of Drug Metabolism and Drug Disposition 1971, Williams & Wilkins, Baltimore, MD. B.N. LaDu, H.G. Mandel, E.L. Way (Eds.).
11. Chronicles of Drug Discovery 1993, Vol. 3. ACS, Washington, DC. D. Lednicer (Ed.).
12. The Organic Chemistry of Drug Design and Drug Action 2004, Elsevier, Oxford, United Kingdom. 2nd ed. R.B. Silverman (Ed.).
13. Comprehensive Medicinal Chemistry 2006, Vol. 1. Elsevier, Oxford, United Kingdom. J. Taylor, D. Triggle (Eds.).
14. Foye's Principles of Medicinal Chemistry 2002, Lippincott Williams & Wilkins, Baltimore, MD. 5th ed. D.A. Williams, T.L. Lemke (Eds.).
15. Burger's Medicinal Chemistry and Drug Discovery, Volume 4 Therapeutic Agents 1997, John Wiley & Sons, New York, NY. 5th ed. M.E. Wolff (Ed.).
16. Archer R. The drug discovery factory-An inevitable evolutionary consequence of high-throughput parallel processing. Nature Biotechnology 1999, 17:834.
17. Bachmann K.A., Ring B.J., Wrighton S.A. Drug-drug interactions and the cytochromes P450. Drug Metabolizing Enzymes-Cytochrome P450 and Other Enzymes in Drug Discovery and Development 2003, 311-336. Fontis Media, Lausanne, Switzerland. J.S. Lee, R.S. Obach, M.B. Fisher (Eds.).
18. Bemis G.W., Murcko M.A. The properties of known drugs 1 molecular frameworks. Journal of Medicinal Chemistry 1996, 39:2887-2893.
19. Bemis G.W., Murcko M.A. Properties of known drugs 2 side chains. Journal of Medicinal Chemistry 1999, 42:5095-5099.
20. Bodor N., Buchwald P. Soft drug design-General principles and recent applications. Medicinal Research Reviews 2000, 20:58-101.
21. Bohm H-J., Stahl M. Structure-based library design-Molecular modeling merges with combinatorial chemistry. Current Opinion in Chemical Biology 2000, 4:283-286.
22. Bondy S.S. The role of automation in drug discovery. Current Opinion in Drug Discovery & Development 1998, 1:116-119.
23. Borman S. Combinatorial chemistry-Redefining the scientific method. Chem Eng News 2000, 78:53-65.
24. Brennan M.B. Drug discovery-Filtering out failures early in the game. Chem Eng News 2000, 78:63-73.
25. Bristol D.W., Wachsman J.T., Greenwell A. The NIEHS Predictive-Toxicology Evaluation Project. Environmental Health Perspectives 1996, 104:1001-1010.
26. Chen X., Wang W. The use of bioisosteric groups in lead optimization. Ann Rep Med Chem 2003, 38:333-346.
27. Cheng S., Comer D.D., Williams J.P., Myers P.L., Boger D.L. Novel solution phase strategy for the synthesis of chemical libraries containing small organic molecules. Journal of the American Chemical Society 1996, 118:2567-2573.
28. Dantzig, A.H., Hillgren, K.M., & Alwis, D.P. Drug transporters and their role in tissue distribution. Ann Rep Med Chem, 39, 279-291.
29. Davies K., White C. Managing combinatorial chemistry information. Molecular Diversity in Drug Design 1999, 175-196. Kluwer Academic Pub, Dordrecht, The Netherlands. P.M. Dean, A.L. Lewis (Eds.).
30. DesJarlais R.L., Sheriden R.P., Seibel G.L., Dixon J.S., Kuntz I.D. Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. Journal of Medicinal Chemistry 1988, 31:722-729.
31. Drews J. Drug discovery-A historical perspective. Science 2000, 287:1960-1969.
32. Eddershaw P.J., Beresford A.P., Bayliss M.K. ADME/PK as part of a rational approach to drug discovery. Drug Discovery Today 2000, 5:409-414.
33. Ehrlich P. Chemotherapeutics-Scientific principles, methods and results. The Lancet 1913, 16:445-451.
34. Erhardt P.W., Gorczynski R.J., Anderson W.G. Conformational analogus of dopamine-Synthesis and pharmacological activity of (E)- and (Z)-2-(3,4-dihydroxyphenyl)-cyclopropylamine hydrochlorides. Journal of Medicinal Chemistry 1979, 22:907-911.
35. Erhardt P.W. Renal vascular dopamine receptor topography-Structure-activity relationships that suggest the presence of a ceiling. ACS Symposium Series, 224, Dopamine Receptors 1983, 275-280. ACS, Washington, DC. C. Kaiser, J.W. Kebabian (Eds.).
36. Erhardt P.W. In search of the digitalis replacement. Journal of Medicinal Chemistry 1987, 30:231-237.
37. Erhardt P.W., Hagedorn A.A., Sabio M. Cardiotonic agents 3-A topographical model of the cardiac c-AMP phosphodiesterase receptor. Molecular Pharmacology 1988, 33:1-13.
38. Erhardt P.W., Chou Y-L. A topographical model for the cAMP phosphodiesterase III active site. Life Sciences 1991, 49:553-568.
39. Erhardt P.W. Esmolol. Chronicles of Drug Discovery 1993, 191-206. ACS, Washington, DC. D. Lednicer (Ed.).
40. Erhardt P.W. Chemotherapeutic agents-Lecture 1. American Journal of Pharmaceutical Education 1997, 61:192-196.
41. Erhardt P.W. Case studies-A prodrug and a soft drug. Drug Metabolism-Databases and High Throughput Testing During Drug Design and Development 1999, 62-69. IUPAC/Blackwell, Geneva, Switzerland. P.W. Erhardt (Ed.).
42. Erhardt P.W. Medicinal chemistry in the new millennium-A glance into the future. Pure and Applied Chemistry 2002, 74:703-785.
43. Erhardt P.W., Matos L. Selective beta-adrenergic receptor blocking agents. Analog-based Drug Discovery 2006, 193-232. IUPAC/ Wiley-VCH Verlag GmbH, Weinheim, Germany. J. Fischer, C.R. Ganellin (Eds.).
44. Erhardt P.W. Case study 'Esmolol Stat'. Analog-based Drug Discovery 2006, 233-246. IUPAC/Wiley-VCH Verlag GmbH, Weinheim, Germany. J. Fischer, C.R. Ganellin (Eds.).
45. Erhardt P.W. Medicinal chemistry in the new millennium-A glance into the future. Drug Discovery and Development Volume 1 Drug Discovery 2006, 17-102. John Wiley & Sons, Hoboken, NJ. M.S. Chorghade (Ed.).
46. Erhardt P.W., Proudfoot J.R. Drug discovery-Historical perspective, current status and outlook. Comprehensive Medicinal Chemistry 2006, Vol. 1. Oxford, United Kingdom. J. Taylor, D. Triggle (Eds.).
47. Floyd C.D., Leblanc C., Whittaker M. Combinatorial chemistry as a tool for drug discovery. Progress in Medicinal Chemistry 1999, 36:91-168.
48. Gillespie P., Goodnow R.A. The hit-to-lead process in drug discovery. Ann Rep Med Chem 2004, 39:293-304.
49. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. Journal of Medicinal Chemistry 1985, 28:849-857.
50. Grimley J. Pharma challenged-Market shifts and generic competition create dynamic environment for drug developers. Chem Eng News 2006, 4:17-28.
51. Hansch C., Fujita T. rho;-σ-π Analysis-A method for the correlation of biological activity and chemical structure. Journal of the American Chemical Society 1964, 86:1616-1625.
52. st century. Current Opinion in Chemical Biology 2000, 4:445-451.
53. Hopkins A.L., Polinsky A. Knowledge and intelligence in drug design. Ann Rep Med Chem 2006, 41:425-437.
54. Houghten R.A., Pinilla C., Blondelle S.E., Appel J.R., Dooley C.T., Cuervo J.H. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 1991, 354:84-86.
55. Horl W.H., George P.M., Carrell R.W., Powers J.C., Zimmerman M., Markwardt F., et al. Inhibition of proteinases. Design of Enzyme Inhibitors as Drugs 1989, 573-649. Oxford Univ Press, Oxford, United Kingdom. M. Sandler, H.J. Smith (Eds.).
56. Jacobs M. Challenging times for patent office. Chem Eng News 2000, 10:39-44.
57. Kuntz I.D. Structure-based strategies for drug-design and discovery. Science 1992, 257:1078-1082.
58. Lau K.F., Sakul H. Pharmacogenetics. Ann Rep Med Chem 2000, 35:261-269.
59. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 1997, 23:3-25.
60. Lumley C. Clinical toxicity-Could it have been predicted? Premarketing experience. Animal Toxicity Studies. Their Relevance for Man 1990, 49-57. Quay Pub, Lancaster, PA. C.E. Lumley, S.R. Walker (Eds.).
61. Martin Y.C. Challenges and prospects for computational aids to molecular diversity. Perspect Drug Discov Res 1997, 7/8:159-172.
62. Merritt A.T. Uptake of new technology in lead optimization for drug discovery. Drug Discovery Today 1998, 3:505-510.
63. Metzger T.G., Paterlini M.G., Portoghese P.S., Ferguson D.M. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Neurochemical Research 1996, 21:1287-1294.
64. Milne G.M. Pharmaceutical productivity-The imperative for new paradigms. Ann Rep Med Chem 2003, 38:383-396.
65. Mitscher L.A., Dutta A. Contemporary drug discovery. Drug Discovery and Development Volume 1 Drug Discovery 2006, 103-128. John Wiley & Sons, Hoboken, NJ. M.S. Chorghade (Ed.).
66. Nirmala N.R. Genomic data mining and its impact on drug discovery. Ann Rep Med Chem 2006, 41:319-330.
67. Ohlstein E.H., Ruffolo R.R., Elliott J.D. Drug discovery in the next millennium. Annual Reviews of Pharmacology and Toxicology 2000, 40:177-191.
68. Patchett A.A., Nargund R.P. Privileged structures-An update. Ann Rep Med Chem 2000, 35:289-298.
69. Pickering L. ADME/tox models can speed up development. Drug Discovery & Development 2001, 1:34-38.
70. Rodrigues A.D. Rational high-throughput screening in preclinical drug metabolism. Med Chem Res 1998, 8:422-433.
71. Sadowski J., Kubinyi H. A scoring scheme for discriminating between drugs and nondrugs. Journal of Medicinal Chemistry 1998, 41:3325-3329.
72. Sarshar S., Zhang C., Moran E.J., Krane S., Rodarte J.C., Benbatoul K.D., et al. 2,4,5-trisubstituted imidazoles-Novel nontoxic modulators of P-glycoprotein mediated multidrug resistance-Part 1. Bioorganic & Medicinal Chemistry Letters 2000, 10:2599-2601.
73. Schmid E.F., Smith D.A. Trends in pharmaceutical innovation. Ann Rep Med Chem 2005, 40:431-441.
74. Seelig A., Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. European Journal of Pharmaceutical Sciences 2000, 12:31-40.
75. Smith P.W., Lai J.Y.Q., Whittington A.R., Cox B., Houston J.G., Stylli C.H., et al. Synthesis and biological evaluation of a library containing potentially 1600 amides/esters-A strategy for rapid compound generation and screening. Bioorganic & Medicinal Chemistry Letters 1994, 4:2821-2824.
76. Tomizawa K., Sugano K., Yamada H., Hori I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. The Journal of Toxicological Sciences 2006, 31:315-324.
77. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry 2002, 45:2615-2623.
78. Walters W.P., Stahl M.T., Murcko M.A. Virtual screening-An overview. Drug Discovery Today 1998, 3:160-178.
79. Waring J.E., Ulrich R.G. The impact of genomics-based technologies on drug safety evaluation. Annual Review of Pharmacologys 2000, 40:335-352.
80. Waterbeemd H., van de, Smith D.A., Beaumont K., Walker D.K. Property-based design-Optimization of drug absorption and pharmacokinetics. Journal of Medicinal Chemistry 2001, 44:1313-1333.
81. Weir M.P., Overington J.P., Schwarz M. Expanding and exploring cellular pathways for novel drug targets. Ann Rep Med Chem 2002, 37:187-196.
82. Wermuth C.G., Ganellin C.R., Lindberg P., Mitscher L.A. A glossary of terms used in medicinal chemistry. Pure and Applied Chemistry 1998, 70:1129-1143.
83. Yoo H.S., Park T.G. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. Journal of Controlled Release 2004, 100:247-256.
84. Zhang C., Sarshar S., Moran E.J., Krane S., Rodarte J.C., Benbatoul K.D., et al. 2,4,5-trisubstituted inmidazoles-Novel nontoxic modulators of P-glycoprotein mediated multidrug resistance-Part 2. Bioorganic & Medicinal Chemistry Letters 2000, 10:2603-2605.